Evidence map›Paper›PMID 41146299›Full record

ArticleMolecular neurodegeneration2025

Modulation of O-GlcNAc cycling influences α-synuclein amplification, degradation, and associated neuroinflammatory pathology.

Yongzhen Miao, Ting Zhang, Zhuoya Ma, Huanhuan Du, Qipei Gu, Mengni Jiang, Kangping Xiong, Chun-Feng Liu, Hongrui Meng

Abstract read
In one paragraph

Article in Molecular neurodegeneration, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yongzhen MiaoInstitute of Neuroscience, Soochow University, Suzhou, Jiangsu, 215123, China.
Ting ZhangInstitute of Neuroscience, Soochow University, Suzhou, Jiangsu, 215123, China.
Zhuoya MaInstitute of Neuroscience, Soochow University, Suzhou, Jiangsu, 215123, China.
Huanhuan DuInstitute of Neuroscience, Soochow University, Suzhou, Jiangsu, 215123, China.
Qipei GuInstitute of Neuroscience, Soochow University, Suzhou, Jiangsu, 215123, China.
Mengni JiangInstitute of Neuroscience, Soochow University, Suzhou, Jiangsu, 215123, China.
Kangping XiongDepartment of Neurology, Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, 215004, China.
Chun-Feng LiuInstitute of Neuroscience, Soochow University, Suzhou, Jiangsu, 215123, China. liuchunfeng@suda.edu.cn.
Hongrui MengInstitute of Neuroscience, Soochow University, Suzhou, Jiangsu, 215123, China. hrmeng@suda.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe accumulation and propagation of α-synuclein (α-syn) are hallmark features of Parkinson's disease (PD) and related neurodegenerative disorders. O-GlcNAcylation, an abundant post-translational modification throughout the brain, is regulated by the enzymatic activity of the cycling enzymes O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA) and has been implicated in altering α-syn toxicity. Nevertheless, the interplay between modulating O-GlcNAc cycling and α-syn aggregation and the propagation of amyloid pathology is not well elucidated.

methodsTo this end, we delivered conformational strains of α-syn in the striatum of mice or neuronal and microglial co-cultured cells following pharmacologically or genetically inhibited OGT and OGA. The substantia nigra was injected with an adeno-associated viral vector coding for α-syn combined with α-syn preformed fibrils to examine α-syn-induced dopaminergic cytotoxicity. The α-syn pathology and spreading, protein O-GlcNAcylation, OGT and OGA levels, microglial inflammation, and behavioral impairments were evaluated. Furthermore, the O-GlcNAc modification and proteolysis status of α-syn under O-GlcNAc cycling modification were also assessed using a combination of approaches, including Click-iT™ O-GlcNAc enzyme labeling, sWGA pulldown, HPLC-MS/MS, and immunohistochemical analysis following proteasome and autophagy-lysosome inhibition.

resultsWe found that modulation of O-GlcNAc cycling, governed by the two enzymes OGT and OGA, significantly affected α-syn aggregation, propagation, dopaminergic neuronal degeneration, and microglial inflammation. Pathological α-syn transmission to adjacent cells and anatomically connected brain regions was found to suppress recipient cellular O-GlcNAc levels, concomitant with reduced OGT expression. Pharmacological inhibition or genetic knockdown of OGT exacerbated α-syn aggregation, enhanced its intercellular transmission, and intensified NOD-, LRR-, and pyrin domain-containing 3 (NLRP3)-mediated microglial inflammation. Conversely, increasing O-GlcNAcylation via OGA inhibition ameliorated these pathological processes. Furthermore, we demonstrate that enzymatic O-GlcNAcylation significantly regulates the aggregation of fibril-induced initial dimer formation and facilitates the clearance of α-syn aggregates through autophagosome-lysosome flux.

conclusionsThese findings highlight the critical regulatory role of O-GlcNAc modification in α-syn pathology and conformational strain formation, and provide mechanical evidence that enhancing O-GlcNAc modifications alleviates pathological α-syn proteolysis by restoring autophagosome-lysosome flux.

Indexed as

Acetylglucosaminealpha-SynucleinN-AcetylglucosaminyltransferasesNeuroinflammatory DiseasesAnimalsbeta-N-AcetylhexosaminidasesHumansMaleMiceMice, Inbred C57BLMicrogliaParkinson DiseaseProtein Processing, Post-TranslationalProteolysisAcetylglucosaminealpha-Synucleinbeta-N-AcetylhexosaminidasesN-AcetylglucosaminyltransferasesO-GlcNAc transferaseNeuroinflammationO-GlcNAcylationProteolysisα-synuclein

Identifiers

PMID41146299
PMCPMC12560605

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.